Kamada Reaffirms 2024 Targets, Unveils 2025 Guidances, Revenue Of $178M-$182M Vs. $171.18M Est. And Adj.EBITDA Of $38M-$42M
Kamada Reaffirms 2024 Targets, Unveils 2025 Guidances, Revenue Of $178M-$182M Vs. $171.18M Est. And Adj.EBITDA Of $38M-$42M
Kamada重申2024年目標，公佈2025年指導，營業收入爲$17800萬，$18200萬對比$17118萬的預估，調整後EBITDA爲$3800萬，$42M
- Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 - $42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on Mid-Point of 2024 Annual Guidance
- Expects to Achieve 2024 Guidance of $158 - $162 Million in Revenue and $32 - $35 Million of Adjusted EBITDA; 2024 Year-End Cash of $78 Million
- Aiming to Secure New Business Development and M&A Transactions During 2025 that Leverage Overall Financial Strength and Existing Commercial Infrastructure to Accelerate Long-Term Growth
- Expansion of Plasma Collection Operations with Opening of a Third Center by End of Q1 2025
- Based on Positive Feedback from U.S. FDA, Kamada Plans to Reduce Inhaled AAT Clinical Study Sample Size to Approximately 180 Patients; Interim Futility Analysis Planned by End of 2025
- 提供2025年度營業收入指導爲178 - 18200萬美元，調整後的EBITDA爲38 - 4200萬美元，較2024年度指導中點相比，營業收入同比增長13%，調整後的EBITDA同比增長19%。
- 預計實現2024年度營業收入指導爲158 - 16200萬美元，調整後的EBITDA爲32 - 3500萬美元；2024年末現金爲7800萬美元。
- 旨在2025年確保新的業務發展和併購交易，利用整體財務實力和現有商業製造行業來加速長期增長。
- 在2025年第一季度結束前擴大血漿採集運營，開設第三個中心。
- 基於美國FDA的積極反饋，Kamada計劃將吸入AAt臨牀研究的樣本量減少至大約180名患者；計劃在2025年底進行中期無效性分析。
資訊熱榜
更新時間